Lawmakers expressed their concerns with proposed cuts to the National Institutes of Health (NIH) during hearings on Capitol Hill.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
In a position statement released today, the American Society of Clinical Oncology (ASCO) stated its strong support for increasing access to investigational new treatment options for patients with cancer, while raising serious concerns about recently proposed federal "right-to-try" (RTT) legislation as well as enacted state RTT laws. ASCO said these measures lack adequate patient protections and do not remove any of the major barriers patients face in accessing investigational drugs outside of clinical trials.
On April 1, Jack F. Whelan, a member of the CancerLinQ® Patient Advisory Committee, received an award from the American Association for Cancer Research for his history of advocacy on behalf of patients with cancer and their family and friends.
Members of ASCO's Leadership Development program participated in a Hill Day to advocate for key cancer policy priorities.
A recent study, “Insurance denials for cancer clinical trial participation after the Affordable Care Act (ACA) mandate”, published in Cancer found that real or perceived lack of coverage of routine cost of cancer clinical trials persist following the passage of the ACA. The authors conclude that these persisting coverage denials and delays remain a substantial barrier to patient participation in cancer clinical trials.
On April 3, 2017, ASCO issued recommendations addressing the needs of sexual and gender minority populations as they relate to cancer.
On March 31, 2017, the U.S. Food and Drug Administration granted regular approval to palbociclib (IBRANCE®, Pfizer Inc.) for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women.
The American Society of Clinical Oncology (ASCO) has released a set of recommendations to enhance the role of observational cancer research in clinical decision-making. Published in the Journal of Clinical Oncology (JCO), the ASCO research statement discusses the expanding opportunities to utilize observational studies to advance cancer research and supplement the knowledge gained through cancer clinical trials.
On March 30, 2017, the U.S. Food and Drug Administration granted regular approval to osimertinib (TAGRISSO® , AstraZeneca Pharmaceuticals, LP) for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
CancerLinQ LLC is partnering with the leading association for hematology/oncology pharmacy professionals, the Hematology/Oncology Pharmacy Association (HOPA).
On March 28, a new article published in JCO Clinical Cancer Informatics (JCO CCI), “Survival Disparities by Hospital Volume among American Women with Gynecologic Cancers” by Brandon-Luke Seagle, MD, et al., that finds that women with ovarian, endometrial or cervical cancer have significantly increased rates of survival if they are treated at higher-volume hospitals.
ASCO's peer-reviewed journals now follow a continuous publication schedule, publishing the newest content from each journal online daily.
On March 27, 2017, the U.S. Food and Drug Administration approved niraparib (ZEJULA™, Tesaro, Inc.), a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
The Centers for Medicare & Medicaid Services (CMS) posted new resources to the Quality Payment Program (QPP) website to help clinicians successfully participate in the first year of the QPP.
On March 15, HIMMS News published an article authored by CancerLinQ LLC Chief Operating Officer Rich Ross that discusses the need for interoperability to for big data efforts to be successful.